selexipag
Actelion’s Uptravi and rare bleeding disorder drug get positive EMA decisions
February 1, 2016Sales and Marketing CHMP, EMA, Uptravi, pulmonary arterial hypertension, selexipag
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has issued positive opinions on …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
Actelion ready to launch Uptravi after FDA approval
December 22, 2015Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag
Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
September 25, 2026
One in three UK women with migraine say symptoms taken less seriously
September 24, 2026
Report highlights scope to expand day surgery
September 23, 2026
Sygnature formalises drug discovery collaboration with X-Chem
September 22, 2026
Codis appoints Steven Facer as chief commercial officer
September 21, 2026
